Ramipril (brand name: Altace) is a type of medicine that belongs to the class of angiotensin-converting enzyme (ACE) inhibitor therapeutics, which lowers the production of angiotensin II (increases blood pressure) and decreases the breakdown of bradykinin (promoted inflammation). It is used to treat disorders such as high blood pressure, diabetic kidney problems, and used as a preventive medication for heat failure, stroke, and cardiovascular deaths on patients of 55 years and above. It can be given as monotherapy or in combination with other cardiovascular drugs in the form of oral dosages.
Impact of COVID-19 on Ramipril Market
Pharmaceutical and biotech companies together with governments around the globe are working to address the COVID-19 outbreak, from supporting the development of vaccines to planning for medicine supply chain challenges. Currently, around 115 vaccine candidates and 155 molecules are in the R&D pipeline. Moreover, commonly used drugs such as hydroxychloroquine have witnessed a dramatic surge in demand for the management of COVID-19. Such high demand for these drugs has presented huge opportunities for manufacturers of COVID-19 management drugs, as many developed countries are facing shortage of these drugs. Thus, the pharmaceutical and biotechnology industries are expected to witness a significant growth in the future, owing to the demand for vaccine and treatment drugs for COVID-19. This, in turn, is expected to have a significant impact on the ramipril market.
Top Impacting Factors
- Increase in prevalence of high blood pressure, hypertension, and other cardiovascular diseases boosts the growth of the ramipril market.
- In addition, improvement in treatment such as advancement in the formulation of the drug and adoption of ACE inhibitors for chronic disorders are the major factors which boost the market growth for ramipril.
- However, side effects of the drugs such as rectum bleeding and stomach cramping hinder the ramipril market growth.
- Conversely, due to increased R&D on the ramipril drug along with emerging market regulations and financial donations from governing bodies create new opportunities in the ramipril market.
Market Trends
New product launches to flourish the market
In 2020, Pfizer Inc., an American multinational pharmaceutical and biotechnology corporation, announced the launch of ramipril for the treatment of COVID-19 (RAMIC), placebo oral capsule for the treatment of heart failure and other cardiovascular problems.
In 2020, Dr. Reddy's Laboratories, an Indian multinational pharmaceutical company, launched Cardiopril 5 Capsule which is used for prevention of stroke, hypertension, and high blood pressure.
Key Benefits of the Report
- This study presents the analytical depiction of the ramipril industry along with the current trends and future estimations to determine the imminent investment pockets.
- The report presents information related to key drivers, restraints, and opportunities along with detailed analysis of the ramipril market share.
- The current market is quantitatively analyzed to highlight the ramipril market growth scenario.
- Porter’s five forces analysis illustrates the potency of buyers & suppliers in the market.
- The report provides a detailed ramipril market analysis depending on competitive intensity and how the competition will take shape in coming years
Questions Answered in the Ramipril Report
- Which are the leading players active in the ramipril market?
- What are the current trends that will influence the market in the next few years?
- What are the driving factors, restraints, and opportunities of the market?
- What future projections would help in taking further strategic steps?
- What is "ramipril"?
- What is "ramipril" market prediction in the future?
Ramipril Market Report Highlights
| Aspects | Details |
 By Type |
|
 By Indication |
|
 By Distribution Channel |
|
 By Region |
|
 Key Market Players | Hikma Pharmaceuticals PLC, Arrow Pharmaceuticals, Brown & Burk, AurobindoPharma, Sanofi, Micro Labs Ltd, Pharmanova limited, ApotexInc, Wockhardt, Perrigo Company plc, CiplaInc, Teva Pharmaceutical Industries Ltd, a.s., Novartis AG, Lupin, ZydusCadila, OpsoninPharma Ltd, Dr. Reddy’s Laboratories Ltd, Amneal Pharmaceuticals LLC, Pfizer Inc, Zentiva Group |
Loading Table Of Content...
